Cronos Slows Q2; Stock Remains in 4-Star Territory Though We See More Upside Elsewhere in Cannabis

Cronos’ second-quarter fiscal-year 2022 results slowed from the first quarter. Net revenue declined 8% and adjusted EBITDA was roughly flat at a loss of CAD 19 million, quarter over quarter. While Cronos continues to dominate the Israeli medical market, the Canadian market continues to be hindered by regulatory delays, competitive pressures from too many licensed producers, or LPs, and consistent strength of the black market. Separately, Cronos is repositioning its Lord Jones brand in the U.S. to adult-use products and away from beauty.